- Active Ingredients
Product Documentation
-
View RMM (RMM- Voriconazole Patient Alert Card)
Last updated on this site: 22 Jul 2025
Made PAC visible for patients
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintVoriconazole Accord 50mg Film-coated Tablets
- PL Number:
- PLGB 20075/1335
- MA Holder:
- Accord Healthcare Limited
- Product Classification:
-
POM
- Product Status:
- Active
Product Documentation
-
View Patient Information Leaflet (PIL - Voriconazole Accord 50 mg, 200 mg film-coated tablets)
Last updated on this site: 15 Aug 2024
IB C.I.2.a - To update sections 4.4, 4.5 and 4.8 of the SmPC in-line reference product, VFEND 50 mg/200 mg film-coated tablets; MAH: Pfizer Europe MA EEIG, Belgium; EU procedure number with outcome: EMEA/H/C/000387/WS/2270). Consequently, the PIL is updated. Additionally, section 4.8 and 5.1 of the SmPC have been updated with editorial changes in line with reference product information.
IB C.I.z - To update section 5.1 of the SmPC with Susceptibility testing breakpoints criteria in line with adoption of revision 3 of the Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections.
View Summary of Product Characteristics (SmPC - Voriconazole Accord 50 mg Film-coated Tablets)Last updated on this site: 15 Aug 2024
IB C.I.2.a - To update sections 4.4, 4.5 and 4.8 of the SmPC in-line reference product, VFEND 50 mg/200 mg film-coated tablets; MAH: Pfizer Europe MA EEIG, Belgium; EU procedure number with outcome: EMEA/H/C/000387/WS/2270). Consequently, the PIL is updated. Additionally, section 4.8 and 5.1 of the SmPC have been updated with editorial changes in line with reference product information.
IB C.I.z - To update section 5.1 of the SmPC with Susceptibility testing breakpoints criteria in line with adoption of revision 3 of the Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaint
For any further assistance, please get in touch.